| Overview |
| bs-2200R-PE-Cy7 |
| LDL Polyclonal Antibody, PE-Cy7 Conjugated |
| FCM |
| Human |
| Mouse |
| Specifications |
| PE-Cy7 |
| Rabbit |
| Full length plasma protein (Human) |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cell membrane |
| _-Lipoprotein; Low density lipoprotein; apolipoprotein B100; apo-B100 |
| LDL and HDL transport both dietary and endogenous cholesterol in the plasma. LDL is the main transporter of cholesterol and cholesteryl esters and makes up more than half of the total lipoprotein in plasma. LDL is absorbed by the liver and other tissues via receptor mediated endocytosis. The cytoplasmic domain of the LDL receptor facilitates the formation of coated pits; receptor-rich regions of the membrane. The ligand binding domain of the receptor recognizes apo-B100 on LDL, resulting in the formation of a clathrin-coated vesicle. ATP-dependent proton pumps lower the pH inside the vesicle resulting dissociation of LDL from its receptor. After loss of the clathrin coat the vesicles fuse with lysozomes, resulting in peptide and cholesteryl ester enzymatic hydrolysis. The LDL receptor can be recycled to the cell membrane. Insulin, tri-iodothyronine and dexamethasome have shown to be involved with the regulation of LDL receptor mediated uptake. The protein component of LDL is apolipoprotein B100. LDL contains 2022% protein, 1015% triglycerides, 2028% phospholipids, 3748% cholesteryl esters and 810% cholesterol. |
| Application Dilution |
| FCM |
1:20-100 |
Powered by Bioz